These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26028917)

  • 1. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
    Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
    J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus Associated with Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial.
    Kojima CA; Nga HS; Takase HM; Bravin AM; Martinez Garcia MFF; Garcia PD; Contti MM; de Andrade LGM
    Exp Clin Transplant; 2018 Jun; 16(3):301-306. PubMed ID: 28836934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
    Bechstein WO; Paczek L; Wramner L; Squifflet JP; Zygmunt AJ;
    Transplant Proc; 2013; 45(6):2133-40. PubMed ID: 23953523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
    Langer RM; Hené R; Vitko S; Christiaans M; Tedesco-Silva H; Ciechanowski K; Cassuto E; Rostaing L; Vilatoba M; Machein U; Ulbricht B; Junge G; Dong G; Pascual J
    Transpl Int; 2012 May; 25(5):592-602. PubMed ID: 22471345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Sirolimus Combined With Tacrolimus and Mycophenolate Mofetil Combined With Tacrolimus in Kidney Transplantation Recipients: A Meta-Analysis.
    Gao L; Xu F; Cheng H; Liu J
    Transplant Proc; 2018 Dec; 50(10):3306-3313. PubMed ID: 30577200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
    Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Hricik DE; Anton HA; Knauss TC; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2002 Jul; 74(2):189-93. PubMed ID: 12151730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.